GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.

Linlin WangJing LiuJinguo LiuXiaoyan ChenMeijia ChangJing LiJian ZhouChunxue BaiYuanlin Song

Published in: Journal of cancer research and clinical oncology (2019)

Our results suggest that GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells. Thus, GLRX may represent a therapeutic target for increasing the efficiency of gefitinib treatment.

Keyphrases

small cell lung cancer
induced apoptosis
tyrosine kinase
epidermal growth factor receptor
advanced non small cell lung cancer
signaling pathway
cell cycle arrest
endoplasmic reticulum stress
oxidative stress
brain metastases
replacement therapy